Corona Remedies’ IPO opens December 8 with a price band of Rs 1008-1062, aiming to raise Rs 655 crore. The company, showing strong revenue and profit growth, has a portfolio of 71 brands, with 27 ‘engine’ brands driving over 72% of domestic sales. Analysts recommend long-term subscription despite concentration risks.